As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let’s look at one noteworthy recent insider buy.
At Cara Therapeutics (CARA), there was insider buying on Thursday, by Director Martin Vogelbaum who purchased 400,000 shares at a cost of $4.87 each, for a total investment of $1.95M. Cara Therapeutics is trading up about 9.3% on the day Monday. Vogelbaum was up about 19.4% on the buy at the high point of today’s trading session, with CARA trading as high as $5.82 at last check today.